Skip to main content
Equibles
BVS logo

BVS · Bioventus Inc.

Track BVS — free

Use BVS with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about BVS

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$14.31 -0.37 (-2.52%)
Market Cap
$1.20B
Shares
84.09M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$14.68 Open$14.35 Day$14.35–14.92 52W close$6.51–15.26 Avg vol 30d761K Short int2.5M · 3.0% float · 3.9d Short vol78% Last earningsAug 5, 2026 DataFeb 2021–Aug 2026 Filing10-Q · Aug 5

Up next

Next earnings call
Nov 4, 2026 Est · unconfirmed · in 11 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 5, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Buy
      SellHoldBuy
      Technical Buy Momentum Very Strong Sentiment Neutral Fundamentals Strong Quant / Vol Very High
      Market backdrop VIX 14.9 · calm Equity put/call 0.52
      Technical
      price trend
      Buy
      50 / 200-day cross No cross
      Price vs 200-day avg +58%
      above
      Price vs 50-day avg +26%
      above
      RSI (14) 66
      neutral
      MACD trend Negative
      52-week position 93%
      near high
      Volume (OBV) Confirms
      volume backs price
      Momentum
      relative strength
      Very Strong
      1-month return +26%
      trailing
      6-month return +66%
      trailing
      YTD return +97%
      this year
      Relative strength +54%
      vs S&P · 6-mo
      Sentiment
      smart money
      Neutral
      Trend (MA cross) No cross
      50d $12 › 200d $9 — 50d above 200d
      Institutional flow Distributing
      -1% holders QoQ · +26 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Falling
      3.02% of float · ▼ -7.1% MoM · 3.9 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      155 holders — near 3-yr high, broad support
      Squeeze score 63
      elevated · 0–100
      Fundamentals
      Strong
      Revenue growth −1%
      Y/Y
      Gross margin 68%
      expanding
      EPS growth +159%
      Y/Y
      Free cash flow $72.1M
      Valuation P/E 18.6
      below peers
      Balance sheet $242.7M
      net debt
      Quant / Vol
      risk profile
      Very High
      Volatility 52%
      annualized · 1-yr
      Max drawdown −28%
      past year
      ATR 4.9%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Guidance & track record

      Beat or met 2 of last 2
      Latest guidance · from the 8-K filed Aug 5, 2026
      Cash from Operations · twelve months ending December 31, 2026 Initiated $84M – $89M
      Adjusted EPS · twelve months ending December 31, 2026 Non-GAAP Initiated $0.75 – $0.79
      Prior guidance period ended · from the 8-K filed Nov 4, 2025
      Non-GAAP EPS · twelve months ending December 31, 2025 $0.64 – $0.68
      Guided vs delivered · last 2 settled
      Net sales 2024
      guided $535M – $550M
      $573.28M Beat +5.7%
      2023 revenue 2023
      guided $498M – $505M
      $512.35M Beat +2.2%

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Buy
      1 · 3 · 3
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      +58% Bullish
      Price vs 50-day avg
      +26% Bullish
      RSI (14)
      66 Neutral
      MACD trend
      Negative Bearish
      52-week position
      93% Bullish
      Volume (OBV)
      Confirms Neutral
      Market signals — smart money & positioning
      Bullish · 2 of 6
      Trend (MA cross) No cross
      50d $12 › 200d $9 — 50d above 200d
      Institutional flow Distributing
      -1% holders QoQ · +26 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Falling
      3.02% of float · ▼ -7.1% MoM · 3.9 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      155 holders — near 3-yr high, broad support
      Price context
      position in its 52-week range
      Range low $7 Now $15 · 93% Range high $15
      vs 200-day avg +58% vs 50-day avg +26%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from written earnings releases and filings
      Metric Latest Period YoY
      Non-GAAP earnings per diluted share non-GAAP $0.22 Q2 2026 —
      Adjusted EPS non-GAAP $0.24 Q4 2025 —

      Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

      Versus peers

      Medical Devices — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      BVS
      Bioventus Inc.
      this stock
      		$1.20B +97.3% -0.9% 18.6 3.0%
      ABT
      Abbott Laboratories
      		 $196.27B -8.7% +5.7% 31.6 1.3%
      SYK
      Stryker Corp
      		 $127.26B -3.3% +11.2% 34.4 2.2%
      MDT
      Medtronic plc
      		 $120.49B -2.0% +8.4% 25.2 1.4%
      BSX
      Boston Scientific Corp
      		 $73.14B -45.5% +12.5% 20.4 1.5%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Accumulating
      Holders
      155
      % held
      64.1%
      Net QoQ
      +2.6M sh
      Top holder
      Essex Woodlands Managemen…
      Held Float
      View
      Held by Funds
      Fund positions
      156
      View
      Short & Settlement
      Short Interest Falling
      Shares short
      2.5M
      Days to cover
      3.9d
      Change
      -193.6K sh
      View
      Short Volume
      Short vol %
      78%
      As of
      Aug 20, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      295
      Value
      $3.9K
      As of
      Jul 30, 2026
      View
      Off-Exchange
      Off-exchange %
      41.9%
      Week of
      Jul 13, 2026
      Off-exch Lit
      View
      Financials
      Financials
      Revenue (FY)
      $568.1M
      Net income (FY)
      $22.7M
      EPS diluted
      $0.33
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Aug 5, 2026
      This year
      10
      View
      Proposed Sales
      Value
      $105.7K
      Shares
      12.0K
      Filed
      Mar 11, 2026
      View
      Earnings & Events
      Earnings Calls
      Last call
      Aug 5, 2026
      View
      Investor Relations
      Latest news
      Bioventus Reports Second Quarter…
      Published
      Aug 5, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      BVS +5.5% +26.2% +65.7% +11.5% +97.3%
      SPY -0.4% +2.9% +11.6% +3.0% +12.8%
      vs SPY +5.9% +23.3% +54.1% +8.5% +84.5%
      Key facts CIK 1665988 CUSIP 09075A108 13F (30d) 146 filings 144 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)